Management of Breakthrough Menstrual Bleeding

Initial Assessment and Treatment

The Centers for Disease Control and Prevention recommends ruling out pregnancy, IUD displacement, sexually transmitted infections, structural pathology, coagulopathies, and medication effects before initiating treatment for breakthrough menstrual bleeding 1, 2, 4
The American College of Obstetricians and Gynecologists suggests that NSAIDs for 5-7 days during bleeding episodes are the first-line treatment for breakthrough menstrual bleeding, regardless of contraceptive method used 1, 2, 3
Multiple NSAIDs, including mefenamic acid, indomethacin, flufenamic acid, and diclofenac sodium, have proven effective in reducing menstrual blood loss 1, 3

For Copper IUD users, the first-line treatment is NSAIDs for 5-7 days during bleeding, and aspirin should be avoided as it may paradoxically increase bleeding in women with lower baseline blood loss 1, 2, 3, 5
For LNG-IUD users, the first-line treatment is NSAIDs for 5-7 days, and the second-line treatment is combined oral contraceptives or estrogen for 10-20 days if medically eligible 1, 2, 5
For Contraceptive Implant users, the first-line treatment is NSAIDs for 5-7 days, and the second-line treatment is combined oral contraceptives or estrogen for 10-20 days if medically eligible 2, 3

When NSAIDs fail or are contraindicated, combined oral contraceptives or estrogen for 10-20 days can be used as second-line treatment 1, 2, 3, 5
Tranexamic acid can reduce bleeding by 40-60% but is contraindicated in women with active thromboembolic disease or history/intrinsic risk of thrombosis 1, 3, 5

If breakthrough bleeding persists despite treatment, consider switching to LNG-IUD, which can reduce menstrual blood loss by 71-95% 3, 4
Counsel patients on alternative contraceptive methods and offer method change if patient finds bleeding unacceptable 1, 2

NSAIDs should be avoided in patients with cardiovascular disease due to increased risk of MI and thrombosis 3, 4
Tranexamic acid is contraindicated in patients with active thromboembolic disease, history of thrombosis/thromboembolism, or intrinsic risk for thrombosis 1, 3, 5
Combined hormonal contraceptives should be used with caution in patients with cardiovascular and thrombotic risk factors, especially in perimenopausal women 4